Please assess the completion status of the following clinical trial:

Trial Title: Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed ovarian epithelial carcinoma~  * Recurrent or persistent disease~    * Must have received greater than or equal to (≥) 2 prior cytotoxic chemotherapy regimens, including ≥ 1 platinum-containing regimen~ * Disease not amenable to curative treatment with surgery and/or radiotherapy~* Must have measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) and/or a serum cancer antigen 125 (CA-125) level that is rising and meets 1 of the following criteria:~  * Serum CA-125 level greater than (\>) upper limit of normal (typically 35 μ/mL) on two evaluations at least 2 weeks apart~ * Serum CA-125 level less than (\<) 35 μ/mL but has risen progressively \> 200% over successive specimens ≥ 2 weeks apart~* Estrogen receptor-positive tumor~* Gynecologic Oncology Group (GOG) performance status 0-3~* Platelet count ≥ 50 x 10\^9/Liter~* Serum creatinine less than or equal to (≤) 2.5 mg/deciliter~* Bilirubin ≤ 1.5 times upper limit of normal (ULN)~* Serum glutamic oxaloacetic transaminase (SGOT) ≤ 3 times upper limit of normal (ULN)~* alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 2.5 times ULN (≤ 5 times ULN in the presence of liver metastases)~* Alkaline phosphatase ≤ 3 times ULN~* Prothrombin time-International Normalized Ratio (INR) ≤ 1.6~* Not pregnant or nursing~* Negative pregnancy test~* Must be sterile or fertile patients must use effective contraception (i.e., double method including ≥ 1 barrier, injectable, implantable, condoms plus spermicide)~* Prior malignancy allowed provided the patient has been disease-free for ≥ 5 years~  * Patients with previously diagnosed basal cell skin cancer are eligible immediately after completing therapy~* No history of bleeding (i.e., disseminated intravascular coagulation or clotting factor deficiency)~* No documented sensitivity to active or inactive excipients of fulvestrant (i.e., castor oil or mannitol)~* Recovered from the effects of prior surgery, radiotherapy, and/or chemoradiotherapy~* At least 3 weeks since prior chemotherapy~* At least 3 weeks since prior complete radiotherapy regimen alone or chemoradiotherapy~  * An incomplete radiotherapy regimen (\< 500 Gray) is allowed within the 3-week time frame~Exclusion Criteria:~* Concurrent hormone replacement therapy~* Prior long-term anticoagulation therapy other than anti-platelet therapy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fulvestrant (Type: EXPERIMENTAL): Fulvestrant 500 milligrams (mg) Day 1; 250 mg Day 1, 29 and every 28 days thereafter.

Based on this trial design, predict the completion outcome and termination type (if applicable).